Big Pharma Quietly Enlists Leading Professors to Justify $1,000-Per-Day Drugs Extremely concerning as politicians (policy makers and decision makers) and the public (paying consumers who want to be healthy) get swayed by scholarly research which they believe to be transparent and honest. Over and over again we see where there is really big money at play, you may not get the best advice. An industry protects itself no matter what the cost to society or individuals. How does one then filter out the good research for the "bad research"? From the article: Over the last three years, pharmaceutical companies have mounted a public relations blitz to tout new cures for the hepatitis C virus and persuade insurers, including government programs such as Medicare and Medicaid, to cover the costs. That isn’t an easy sell, because the price of the treatments ranges from $40,000 to $94,000 — or, because the treatments take three months, as much as $1,000 per day. To persuade payers and the public, the industry has deployed a potent new ally, a company whose marquee figures are leading economists and health care experts at the nation’s top universities. The company, Precision Health Economics, consults for three leading makers of new hepatitis C treatments: Gilead, Bristol-Myers Squibb, and AbbVie. When AbbVie funded a special issue of the American Journal of Managed Care on hepatitis C research, current or former associates of Precision Health Economics wrote half of the issue. A Stanford professor who had previously consulted for the firm served as guest editor-in-chief. At a congressional briefing last May on hepatitis C, three of the four panelists were current or former Precision Health Economics consultants. One was the firm’s co-founder, Darius Lakdawalla, a University of Southern California professor. See http://ift.tt/2mgg15j
Comments